Nyhed | Nyhed 24/01
Ugeskr Læger 2008;170(25):2256
Summary The use of adalimumab in severe fistulising Crohn's disease - three cases Ugeskr Læger 2008;170(25):2256 So far infliximab is the only approved anti-TNF-α antibody for patients with Crohn's disease. Development of antibodies to infliximab may result in allergic reactions or reduced effect. We report three patients who received adalimumab, which induced longstanding remission in all three patients.